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ABSTRACT
The delayed availability of vaccine during the 2009 H1N1 influenza pandemic created a sense of urgency to
better prepare for the next influenza pandemic. Advancements in manufacturing technology, speed and
capacity have been achieved but vaccine effectiveness remains a significant challenge. Here, we describe a
novel vaccine design strategy called immune engineering in the context of H7N9 influenza vaccine devel-
opment. The approach combines immunoinformatic and structure modeling methods to promote protec-
tive antibody responses against H7N9 hemagglutinin (HA) by engineering whole antigens to carry seasonal
influenza HA memory CD4+ T cell epitopes – without perturbing native antigen structure – by galvanizing
HA-specific memory helper T cells that support sustained antibody development against the native target
HA. The premise for this vaccine concept rests on (i) the significance of CD4+ T cell memory to influenza
immunity, (ii) the essential role CD4+ T cells play in development of neutralizing antibodies, (iii) linked
specificity of HA-derived CD4+ T cell epitopes to antibody responses, (iv) the structural plasticity of HA and (v)
an illustration of improved antibody response to a prototype engineered recombinant H7-HA vaccine.
Immune engineering can be applied to development of vaccines against pandemic concerns, including
avian influenza, as well as other difficult targets.
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Introduction
The need to prepare for infectious disease outbreaks to pre-
vent catastrophic loss of life and societal disruption drives
innovative vaccine development. New technologies present
opportunities to meet the challenge faced when long standing
technologies do not yield effective vaccines. Here, in the
context of avian H7N9 influenza, we present a novel antigen
design strategy combining immunoinformatic and structure
modeling technologies to harness both T cell and B cell
immune mechanisms to produce more effective vaccines.
Concern for an avian H7N9 influenza pandemic
In 2013, the first cases of human infection with avian influ-
enza A (H7N9) were reported in mainland China.1,2 Since
then, China has experienced five epidemics of human infec-
tion with H7N9.3,4 Outbreaks typically occur in a seasonal
pattern peaking during January-March and dropping off by
end of May. This trend, however, may be changing. The fifth
outbreak of H7N9 began in October 2016 with a spike in cases
in December.4 Along with an earlier onset of reported cases,
there was also a sudden increase in human H7N9 cases
reported.3,5,6 Of the total number of human H7N9 infections
identified since 2013, 52% of cases have occurred during the
latest outbreak.7 As of March 2018, a total of 1,567 cases of
laboratory confirmed H7N9 infections were detected with at
least 615 deaths reported.8 The high case fatality rate asso-
ciated with avian H7N9 infection poses a continuing threat to
human health. In addition to an increase in H7N9 human
infection, the cases reported have spread into western pro-
vinces for the first time.3–5 Changes in distribution were also
noted during the fifth wave from affecting mostly elderly to
middle aged adults, as well as an increase in cases from urban
areas to suburban and rural areas.3,5
Human H7N9 infections have been largely zoonotic
through exposure to infected poultry.9 An epidemiological
study in China between May 2013 and May 2014 showed
6.7% of case contacts developed H7N9 antibodies, suggesting
that human-to-human transmission occurs and could cause
mild or asymptomatic infection.10 Both human-to-human
household and hospital clusters have been described.11,12
Transmissibility of avian influenza to humans depends on a
balance of activities of the viral surface glycoproteins HA and
neuraminidase (NA). The vast majority of human H7N9 iso-
lates bears the hallmark Q226L mutation in HA that confers
human receptor binding (α-2,6-linked galactose) and reduces
avian receptor binding (α-2,3-linked galactose).13 N9-NA also
demonstrates receptor binding properties with a preference to
binding human α-2,6 linkages.14 Of note, before the fifth
outbreak, human infections were caused by a low pathogenic
avian influenza, which caused little or no disease in infected
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poultry.6 However, in February of 2017 the National Health
and Family Planning Commission of China reported genetic
sequences from virus isolates from two patients located in
Guangdong Province that had insertions at the HA gene
cleavage site which is suggestive of a highly pathogenic avian
influenza.6,7 Additionally, mutations in the viral polymerase
that may augment replication and pathogenicity in humans
have been observed, however human cases of highly patho-
genic H7N9 virus infection do not exhibit increased transmis-
sion and virulence.15 Combined with already existing
adaptations in H7N9 for increased viral replication in the
mammalian lower respiratory tract16, the potential for further
adaptations that increase human-to-human transmissibility
raises concern for an H7N9 influenza virus pandemic, despite
lower incidence in recent months than in previous years.
Challenges to preparedness for an avian H7N9
influenza pandemic
Historically, vaccination has been the most effective strategy to
control seasonal influenza spread and is the basis for efforts to
develop avian influenza vaccines. Relative to seasonal influenza,
vaccination against avian influenza poses a unique challenge
because the human population is immunologically naïve.17
Vaccination cannot rely on preferential recruitment of memory
B and T cells to elicit a protective antibody response due to
distant sequence relatedness with seasonal influenza. Any
cross-reactive memory B and T cells would be present at
frequencies too low to confer protective antibody immunity
by seasonal vaccination.18 As a consequence, avian influenza
vaccines require higher doses than seasonal vaccines or adju-
vant formulation to stimulate robust immune responses.18
H7N9 influenza HA elicits weak neutralizing antibody
responses in natural infection and vaccination. H7N9-
infected humans display delayed development of the correlate
of influenza protection, hemagglutination inhibition (HI)
antibodies, when compared to seasonal influenza infection;
IgG avidity for H7N9 HA is also significantly lower.19 One
report showed only 10% of subjects seroconverted in a Phase I
trial of a live attenuated H7N9 vaccine.20 The results of alter-
native vaccine strategies have also been subpar with both
inactivated H7N9 split vaccine and H7N9 HA virus-like par-
ticle vaccine eliciting HI seroconversion rates of only 6% and
15.6% in Phase I trials respectively.21,22 This compares poorly
with the ~ 89% rate reported for similar seasonal influenza
subunit vaccines.23–25 Even with the addition of adjuvant and
a booster injection, the inactivated split H7N9 vaccine elicited
HI seroconversion in only 59% of subjects in an early Phase II
clinical trial.26 More recently, a two-dose AS03-adjuvanted
inactivated virus vaccine showed 86–96% seroconversion for
different antigen doses and adjuvant formulations three weeks
after the boost immunization but these rates dropped off
significantly by the six-month time point.27 Compared to
seasonal H1-HA and H3-HA, fewer CD4+ T cell epitopes
have been found in H7N9 HA.28 Additionally, conservation
of T cell epitopes with other strains of influenza was very
limited29. To better prepare for an H7N9 influenza pandemic,
vaccine strategies that overcome the poor immunogenicity of
novel H7N9 HA are needed. To address this challenge, T cell
epitope engineering of HA aimed at recalling memory CD4+
T cell to seasonal influenza is a promising strategy that may be
utilized to create a vaccine with improved immunogenicity
and efficacy.
Memory CD4+ T cells contribute to protection against
influenza
The role memory CD4+ T cells play in pandemic influenza A
H1N1 (pH1N1) immunity demonstrates the potential to har-
ness pre-existing seasonal HA-specific CD4+ T cells to pro-
duce a more potent H7N9 vaccine. A study of human pH1N1
infection in individuals with no pre-existing protective anti-
bodies showed that cross-reactive memory CD4+ T cells cor-
relate with lower virus shedding and less severe illness.29
Similarly, mice exposed to pre-pandemic H1N1 develop
memory CD4+ T cells that protect against pH1N1
infection.30 In clinical vaccine studies, a single dose of mono-
valent pH1N1 vaccine generates neutralizing antibodies, sug-
gesting that memory CD4+ T cells are able to support naïve B
cell responses to a novel HA.31–33 Importantly, it was shown
that T cell epitopes common to pH1N1 and pre-pandemic HA
stimulated memory CD4+ T cell responses; epitopes unique to
pH1N1 HA failed to mount a significant CD4+ T cell
response.34 This could be one of various reasons that explain
the poor antibody response to H7N9 influenza. Epitope pre-
dictive algorithms found 11 putative, broadly reactive CD4+ T
cell epitopes, of which only four are conserved in seasonal
influenza. This contrasts with 16 broadly reactive epitopes
found in pH1-HA, of which 13 are conserved in pre-
pandemic H1-HA.29 Furthermore, an H7-HA peptide screen
showed that only ~ 60% of persons never exposed to H7N9
influenza develop CD4+ T cell responses, primarily to
sequences found in the HA2 domain in regions highly con-
served with H3-HA.34 While seasonal influenza elicits mem-
ory CD4+ T cells that cross-react with H7-HA epitopes, it
appears to be insufficient to generate protective antibodies in
H7N9 vaccination. Given the advantages memory CD4+ T
cells offer – higher frequencies and lower thresholds for anti-
gen stimulation and co-stimulation in comparison with naïve
cells35-37 – a vaccine strategy that potentiates memory CD4+ T
cell recall may improve H7N9 vaccine responsiveness.
CD4+ T cell help is required for antibody
development
Neutralizing antibodies are considered the best correlate of
vaccine efficacy for the majority of licensed vaccines.
Generation of antibody after vaccination depends on follicular
helper T cells (Tfh), a subset of CD4+ T cells that are specia-
lized for providing help to B cells to support class switch
recombination, affinity maturation, and B cell differentiation
into long-lived plasma cells and memory cells in germinal
centers (GC) in secondary lymphoid tissue.38,39 A signature
Tfh marker, CXCR5, is upregulated on naïve CD4+ T cells
after antigen stimulation, permitting localization to the B cell
zones of lymphoid tissue.40,41 Mature Tfh cells expressing
PD-1, ICOS and Bcl-6 provide signals for B cell survival and
differentiation via CXCL13, IL-4 and IL-21 production as well
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as CD40L expression. In humans, where access to lymphoid
tissue is not feasible, circulating Tfh cells are surrogates for
understanding human immune responses to vaccination.42
Like GC Tfh, circulating Tfh express CXCR5 and PD-1,
secrete IL-21 and are able to promote B-cell differentiation
in vitro.43 Circulating ICOS+CXCR3+CXCR5+ Tfh are asso-
ciated with protective antibody responses after seasonal influ-
enza vaccination in young adults.44,45 Thus, a vaccine strategy
that boosts Tfh responses may improve H7N9 vaccine respon-
siveness by inducing CD4+ T cells.
HA-specific CD4+ T cells are linked to neutralizing
antibody responses
CD4+ T cells exhibit a range of functions, including cytotoxi-
city and support for memory CD8+ T cell development, in
addition to providing help to B cells for neutralizing antibody
production. An H7N9 vaccine strategy that focuses the CD4+
T cell response on development of increased HI antibody
titers would improve vaccine responsiveness. Recent studies
have shown that antigen specificity of CD4+ T cells respond-
ing to influenza vaccination is linked to neutralizing antibody
responses.34,46 Mice that develop CD4+ T cell memory to HA
exhibit enhanced neutralizing antibody levels and lower lung
viral titers in comparison with mice bearing nucleoprotein-
specific CD4+ T cell memory.47 Linked specificity is also
observed in humans who receive inactivated virus vaccine,
which contains internal proteins in addition to the critical
antigen HA. Monovalent pandemic H1N1 and H5N1 vacci-
nation studies show that HI titers correlate with HA-specific
CD4+ T cell expansion, but do not track with NP-specific
CD4+ T cell levels.34,46 Moreover, circulating Tfh in humans
are predominantly HA-specific.48 These studies suggest a vac-
cine strategy that boosts protective antibody responses via
memory CD4+ T cell induction could rely on HA-derived
epitopes, despite closer sequence identity between seasonal
and avian influenza internal antigens.
HA has a high tolerance for mutations
Another rationale for introducing seasonal HA CD4+ T cell
epitopes into H7N9 HA is the remarkable capacity for influ-
enza HA to tolerate mutations without compromising its
structural and essential functional properties. As many as 18
different HA subtypes have been described, suggesting that
the protein structure can accommodate a wide variety of
amino acid substitutions.49 Notably, a recent study showed
that when mutant viruses that incorporated ~ 10,000 single
amino acid mutations to HA were generated, viruses that
successfully replicated could accomodate mutations at any
site in the protein other than those involved in receptor
binding to host cells.50 This extraordinary tolerance for muta-
tion makes HA an ideal target for rationale design, where
memory CD4+ T cell epitopes from seasonal HA are intro-
duced into their corresponding locations in avian HA. Despite
the relative low risk, care must be taken when making
sequence modifications to avoid perturbation of the global
HA fold and neutralizing epitopes that are needed to raise
HI antibodies that recognize the wild type HA circulating in
nature. With the availability of molecular modeling and simu-
lation methods, it is feasible to strike a balance between
preserving structure and improving immunogenicity to
rationally design vaccines for production and immunogenicity
and efficacy testing. Indeed, this is akin to a strategy we and
others use to address the challenge of biologic drug
immunogenicity.51–53 While the goal for biologics is to reduce
anti-drug antibodies, in contrast with objective of vaccination,
sequence modifications that delete CD4+ T cell epitopes have
been successfully balanced with maintaining biologic structure
and activity to improve drug safety and efficacy.
First generation immune engineered H7N9 HA
We designed a novel H7N9 HA vaccine that illustrates the
immune engineering concept. Using immunoinformatic meth-
ods, we predicted H7-HA297-309 to be a promiscuous CD4
+ T
cell epitope that may induce a regulatory T cell (Treg) response,
which could be another reason for the delayed and weak HI
responses in natural H7N9 influenza infection and in vaccine
trials. We found that this sequence activates human
CD4+CD25highCD39+FoxP3+ Tregs and suppresses H7N9-
specific effector (IFNγ+) T cell responses measured by
ELISpot assay in naïve individuals.54 To engineer an antigeni-
cally improved vaccine, we made three amino acid substitu-
tions in H7-HA that introduced the corresponding sequence in
H3-HA (H3-HA306-318), a highly conserved and broadly reac-
tive CD4+ T cell epitope. Structural modeling suggested that
the H7-HA structure could accommodate these substitutions
without destabilizing the protein, enabling introduction of this
epitope to enhance immunogenicity. Not only have there been
very large numbers of exposures to this epitope over many
influenza seasons, but also > 95% of infected humans may
have developed H3-HA306-318-specific CD4
+ T cell memory
because the epitope binds all eight class II HLA supertype
alleles.55,56 Indeed, this epitope is commonly used as a positive
control for influenza immunoreactivity in cellular assays.
Therefore, a novel H7N9 HA vaccine bearing H3-HA306-318
could preferentially recruit memory CD4+ T cells and simulta-
neously avoid Treg induction to increase antibody responses to
this otherwise poorly immunogenic HA.
Characterization of the engineered rHA (H7-HA-Opt1) and
comparison to the wild type rHA demonstrated both preserved
antigenicity and improved immunogenicity in humanized
mice.57 Three monoclonal antibodies raised against wild type
H7-HA recognized H7-HA-Opt1 with affinity equivalent to the
wild type protein, suggesting that modifications did not induce
significant structural perturbations. Similarly, human polyclo-
nal sera demonstrated identical binding profiles against H7-HA
-Opt1 and wild type H7-HA.57 Importantly, immunizations of
NOD/SCID/JAK3(null) immune-deficient mice reconstituted
with human PBMCs (N = 8) using non-adjuvanted H7-HA-
Opt1, stimulated a 5-fold greater anti-H7-HA IgG titer and 20-
fold greater anti-H7-HA B cell frequency over mice immunized
with wild type protein. Taken together, these experimental data
provide evidence that CD4+ T cell epitopes significantly affect
the immunogenicity of H7N9 influenza vaccines and should be
taken into consideration in vaccine design.
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Conclusions
H7N9 viruses, along with many other emerging influenza sub-
types, demonstrate the necessity to develop faster, more effica-
cious vaccines against potential pandemics. Advances in
immunoinformatic methods coupled with structure modeling
allow us to create vaccines that enrich for immunogenic T cell
epitopes as a strategy to enhance both the antibody and cellular
responses against H7N9 antigens. In addition, immune engi-
neering can be applied as a vaccine design strategy for other
pathogens to optimize promising antigens that are intrinsically
poorly immunogenic due to lack of CD4+ effector T cell-
inducing or presence of regulatory T cell-inducing epitopes.
This strategy may prove to be critical against pathogens capable
of rapid spread and causing high numbers of severe illness and
death in an immunologically naïve population.
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